Clinical Trials
3
Active:1
Completed:2
Trial Phases
2 Phases
Early Phase 1:1
Not Applicable:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Not Applicable
2 (66.7%)Early Phase 1
1 (33.3%)Prospective Pilot Study of Robot-assisted Nipple Sparing Mastectomy (RNSM)
Not Applicable
Active, not recruiting
- Conditions
- Anatomic Stage IIB Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Prophylactic MastectomyDuctal Breast Carcinoma In SituPrognostic Stage IB Breast Cancer AJCC v8
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- William Carson
- Target Recruit Count
- 4
- Registration Number
- NCT04537312
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery
Early Phase 1
Completed
- Conditions
- Stage IV MelanomaStage IV Ovarian Epithelial CancerStage IV Breast CancerStage IV Ovarian Germ Cell TumorMale Breast CancerRecurrent MelanomaUnspecified Adult Solid Tumor, Protocol SpecificHepatocellular Carcinoma
- Interventions
- Other: Correlative Studies
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2022-12-06
- Lead Sponsor
- William Carson
- Target Recruit Count
- 1
- Registration Number
- NCT02013492
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Recombinant Interferon Alfa-2b in Treating Patients With Melanoma
Not Applicable
Completed
- Conditions
- Stage IIA Skin MelanomaStage IIB Skin MelanomaStage IIIB Skin MelanomaStage IV Skin MelanomaStage IB Skin MelanomaStage IIC Skin MelanomaStage IIIA Skin MelanomaStage IIIC Skin MelanomaStage IA Skin Melanoma
- First Posted Date
- 2011-10-27
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- William Carson
- Target Recruit Count
- 34
- Registration Number
- NCT01460875
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
News
No news found